ALEC · Alector, Inc.
$1.93
+0.12 (+6.52%)
At close · Oct 5
Return incl. dividend (before tax)
Market Cap
$215.50M
Shares
111.66M
Volume · Oct 5
89.98M
Avg daily vol (3M)
1.17M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.81
Open$1.89
Day$1.80–1.97
52W close$1.14–3.32
Avg vol 30d1.2M
Short int6.1M · 5.5% float · 3.3d
Short vol56%
Last earningsOct 5, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Apr 6, 2027
Est · unconfirmed
· in 26 wks
filed Aug 6, 2026
call held Aug 7, 2025
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
-42.7%
Trailing year
Short interest
5.5%
Latest settlement · 3.3 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Weak
Sentiment
Bullish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.59
Technical
price trend
50 / 200-day cross
Golden cross
Price vs 200-day avg
−9%
below
Price vs 50-day avg
−10%
below
RSI (14)
39
neutral
MACD trend
Negative
52-week position
31%
mid-range
Momentum
relative strength
1-month return
−28%
trailing
6-month return
−22%
trailing
YTD return
+16%
this year
Relative strength
−35%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
Golden cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Accumulating
+2% holders QoQ · +13 funds added
Insider flow
Distributing
Net -$296.1K over 90 days · 100% sells
Short interest
Falling
5.47% of float · ▼ -1.0% MoM · 3.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
141 holders — mid 3-yr range
Squeeze score
49
elevated · 0–100
Fundamentals
Revenue growth
−79%
Y/Y
EPS growth
−13%
Y/Y
Free cash flow
$-184.1M
Balance sheet
$56.1M
net cash
Quant / Vol
risk profile
Volatility
95%
annualized · 1-yr
Max drawdown
−66%
past year
ATR
8.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Prior guidance
period ended
· from the 8-K filed Nov 6, 2025
Collaboration revenue
· 2025
$13M – $18M
Total research and development expenses
· 2025
$130M – $140M
Total general and administrative expenses
· 2025
$55M – $65M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
Golden cross
Bullish
Price vs 200-day avg
−9%
Bearish
Price vs 50-day avg
−10%
Bearish
RSI (14)
39
Neutral
MACD trend
Negative
Bearish
52-week position
31%
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
Golden cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Accumulating
+2% holders QoQ · +13 funds added
Insider flow
Distributing
Net -$296.1K over 90 days · 100% sells
Short interest
Falling
5.47% of float · ▼ -1.0% MoM · 3.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
141 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1
Now $2 · 31%
Range high $3
vs 200-day avg -9%
vs 50-day avg -10%
50-day above 200-day golden cross
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ALEC
this stock
Alector, Inc.
|
$215.50M | +16.0% | -79.1% | — | 5.5% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ALEC | -7.2% | -27.9% | -22.3% | -2.2% | +16.0% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -7.0% | -27.4% | -34.5% | -3.1% | +3.2% |